GBS - GBS STOCK NEWS

GBS Inc. (Nasdaq: GBS) announced significant changes to its executive leadership as it enters a new phase focused on product development. Professor Steven Boyages, PhD, has been appointed Interim CEO, effective October 29, 2021. With extensive experience in healthcare, he aims to enhance GBS's management capabilities. Harry Simeonidis will transition to President Asia Pacific, Sales & Marketing, continuing to support the company's strategic focus on the APAC markets. GBS specializes in non-invasive diagnostic testing, particularly for diabetes, and is pursuing further innovation in this field.

GBS Inc. has filed a Pre-Submission package with the FDA to validate its clinical studies for a saliva-based glucose biosensor. This step allows for FDA feedback on clinical trial plans, aiming to create a non-invasive, real-time glucose monitoring solution for diabetes management. Initial trials will recruit 20-40 subjects and explore the correlation between salivary and plasma glucose. Recently, GBS was awarded a $4.7 million grant from the Australian Government to establish a biosensor manufacturing facility, supporting its mission to transform diabetes monitoring.

GBS (Nasdaq: GBS) announced its participation in two investor conferences: the H.C. Wainwright 23rd Global Investment Conference from September 13-15 and the Benzinga Healthcare Small Cap Conference on September 29-30. An on-demand corporate presentation will be available from September 13 for 90 days. Investors can access webcasts through GBS's website. The company focuses on developing non-invasive, real-time diagnostic tests for diabetes management.

GBS Inc. (NASDAQ: GBS) announced a $4.7 million government grant to build a high-tech manufacturing facility, reflecting confidence in its technology. The company reported $12.7 million in cash and equivalents as of June 30, 2021, providing a runway into Q4 2022. Following its initial public offering, which raised $21.6 million, GBS is advancing its non-invasive diagnostic solutions, particularly a saliva glucose test. The company has secured partnerships with renowned institutions like Johns Hopkins University and Harvard's Wyss Institute to accelerate product development.

GBS Inc. (Nasdaq: GBS) will release its financial results for the fourth quarter and full year ended June 30, 2021, on August 11, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results. GBS specializes in developing non-invasive, real-time diagnostic testing solutions for diabetes management. Stakeholders are encouraged to participate via the provided links and phone numbers for the toll-free and international lines. The webcast will be available for replay on the company's website.

GBS (Nasdaq: GBS) announced a partnership with L.E.K. Consulting to identify commercial partners for distribution in China within two months. A global survey revealed 90% of patients support GBS’s non-invasive glucose monitoring solution, with 70% seriously interested in purchasing. By 2025, China’s diabetic population is projected to reach 70 million. GBS aims to capture a significant share of the type 2 diabetes market, utilizing the Saliva-Glucose Diabetes Test (SGBT) as a pain-free alternative to blood tests. The technology is being developed for additional applications, targeting 130 indications.

GBS (Nasdaq: GBS) has secured a USD $4.7 million grant from the Australian Federal Government to establish a Biosensor manufacturing facility. This initiative aligns with the Government's Modern Manufacturing Strategy and aims to produce the Saliva Glucose Biosensor (SGB), a non-invasive diabetes testing solution. The facility will have a capacity of 100M biosensor units annually. GBS is also developing a COVID-19 antibody biosensor in collaboration with the Wyss Institute at Harvard. The company plans to ultimately tailor the biosensor technology for 130 health indications.

GBS Inc. (GBS) reported Q1 2021 results, highlighting a net loss of $2.6 million, increased from $0.11 million in Q1 2020. The company's cash and equivalents stand at $14.2 million, down from $19.8 million in Q4 2020, providing a runway into Q2 2022. GBS aims for Emergency Use Approval for its SARS-CoV-2 Antibody Biosensor in H2 2021, with ongoing collaborations with institutions like Johns Hopkins and the Wyss Institute. The company is also advancing its Saliva Glucose Biosensor for regulatory submission, emphasizing progress in commercialization plans.